Skin cancer almost defeated? Modern and Merck developed a personalized mRNA vaccine against melanoma, one of the most dangerous types of skin cancer.
In a clinical trial involving 1,137 patients after tumor removal, the combination of vaccine and immunotherapy reduced the risk of relapse or death by 42%. Two years later, in 82.2% of the patients who received a new treatment, the disease did not return. how does it work The vaccine is created individually, taking into account the genetic characteristics of the tumor. It helps the immune system recognize and attack cancer cells.
This is an important step towards personalized oncology. There is still a long way to go before beating melanoma, but the results give cause for cautious optimism.